SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy—A Prospective Observational Cohort Trial. The gene discussed is SLC5A2; the disease is cardiomyopathy.